Invesco DB Agriculture Fund vs Erasca Inc. Common Stock — how do they compare? Invesco DB Agriculture Fund trades at $28.53 (market cap $1.33B), while Erasca Inc. Common Stock trades at $15.57 (market cap $4.95B). The key difference: Erasca Inc. Common Stock is far larger — about 3.7× Invesco DB Agriculture Fund's market cap, and Invesco DB Agriculture Fund is trading nearer its 52-week high, Erasca Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Erasca Inc. Common Stock for 0 Days on average.
| DBA | ERAS | |
|---|---|---|
Market Cap | $1.33B | $4.95B |
Volume | 991,157 | 3,834,689 |
52-Week High | $29.49 | $22.47 |
52-Week Low | $25.44 | $2.20 |
Typical Hold Time | 24 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $4.72B |
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.49, down 1.25% today but maintains strong YTD performance with 12.4% returns. The technical outlook remains bullish with moving averages signaling strength, though oscillators show neutral momentum. Recent news highlights agricultural ETF outperformance driven by weather risks and geopolitical tensions supporting commodity prices.
The fund's diversified agricultural futures exposure and 3.25% yield provide defensive characteristics amid market volatility. Key risks include high expense ratios (0.85%) and commodity price sensitivity. Analyst sentiment is mixed with Seeking Alpha maintaining a Hold rating while noting bullish consolidation near all-time highs since 2020.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →